Palm Beach Gardens, FL, United States of America

Ronald Rahaim

This inventor holds 1 USPTO granted patent. Top assignee: Scripps Research Institute. Active years: 2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ronald Rahaim. Retrieved from https://idiyas.com/inventor/ronald-rahaim

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Ronald Rahaim

Introduction

Ronald Rahaim is an accomplished inventor based in Palm Beach Gardens, FL (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target specific biological pathways.

Latest Patents

One of his notable patents is related to Wee1 degradation inhibitors. The invention provides compounds that inhibit the degradation of Wee1. The compounds of the present invention are generally N-((1H-benzo[d]imidazol-2-yl)methyl)-9H-purin-6-amines. These compounds can be utilized for the treatment of various medical conditions where inhibition of Wee1 is indicated, such as cancer, Alzheimer's disease, neurological disorders, psychiatric disorders, or inflammation-related disorders. Ronald holds 1 patent in this area.

Career Highlights

Ronald Rahaim is associated with The Scripps Research Institute, where he has been involved in groundbreaking research. His work focuses on developing innovative therapeutic strategies that can potentially improve patient outcomes in various diseases.

Collaborations

He has collaborated with notable colleagues, including William R. Roush and Mathieu Bibian, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Ronald Rahaim's contributions to medicinal chemistry and his innovative patent on Wee1 degradation inhibitors highlight his commitment to advancing medical science. His work continues to pave the way for new treatments that address critical health challenges.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…